Prestige BioPharma Limited (KRX:950210)
South Korea · Delayed Price · Currency is KRW 5,860.00
+40.00 (0.69%)
At close: Sep 22, 2026
Prestige BioPharma Market Cap
Prestige BioPharma has a market cap or net worth of 70.43 billion as of September 22, 2026. Its market cap has decreased by -60.11% in one year.
Market Cap
70.43B
Enterprise Value
174.69B
Revenue
16.21B
Ranking
n/a
PE Ratio
n/a
Stock Price
5,860.00
ChartMarket Cap Chart
Since May 28, 2021, Prestige BioPharma's market cap has decreased from 360.58B to 70.43B, a decrease of -80.47%. That is a compound annual growth rate of -26.42%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 22, 2026 | 70.43B | -54.40% |
| Dec 30, 2025 | 154.45B | -14.96% |
| Dec 30, 2024 | 181.61B | 59.39% |
| Dec 28, 2023 | 113.94B | 29.33% |
| Dec 29, 2022 | 88.10B | -64.84% |
| Dec 30, 2021 | 250.60B | -30.50% |
| May 28, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Helixmith | 140.44B |
| Genexine | 131.89B |
| Vaxcell-Bio Therapeutics | 100.24B |
| MedPacto | 93.23B |
| iNtRON Biotechnology | 87.42B |
| ENCell | 73.02B |
| Amicogen | 63.41B |
| ORIENT BIO | 54.13B |